鹏华量化先锋混合（005632）成立日期2018年2月23日，最新规模1.17亿。今年以来收益38.28%，同类 排名2189/8155；近一年收益38.28%，同类排名2189/8155；成立以来收益91.29%。 鹏华量化先锋混合（005632）基金经理为时赟超。 截至发稿，时赟超累计任职时间1年9天，现任基金资产总规模25.9亿元，任职期间最佳基金回报 40.5%， 任职期间最差基金回报-0.16%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 1月5日，科美诊断涨5.18%，截至发稿，报7.72元/股，成交2515.13万元，换手率0.83%，总市值30.97亿 元。 资料显示，科美诊断技术股份有限公司位于北京市海淀区永丰基地丰贤中路7号北科现代制造园孵化楼 一层、六层，成立日期2007年5月10日，上市日期2021年4月9日，公司主营业务涉及临床免疫化学发光 诊断检测试剂和仪器的研发、生产和销售。主营业务收入构成为：LiCA系列产品93. ...

11月21日，科美诊断跌5.22%，成交额5332.56万元。两融数据显示，当日科美诊断获融资买入额594.64 万元，融资偿还547.48万元，融资净买入47.16万元。截至11月21日，科美诊断融资融券余额合计1.65亿 元。 融资方面，科美诊断当日融资买入594.64万元。当前融资余额1.65亿元，占流通市值的5.38%，融资余 额低于近一年30%分位水平，处于低位。 资料显示，科美诊断技术股份有限公司位于北京市海淀区永丰基地丰贤中路7号北科现代制造园孵化楼 一层、六层，成立日期2007年5月10日，上市日期2021年4月9日，公司主营业务涉及临床免疫化学发光 诊断检测试剂和仪器的研发、生产和销售。主营业务收入构成为：LiCA系列产品93.42%，CC系列产品 6.58%。 截至9月30日，科美诊断股东户数1.04万，较上期减少0.60%；人均流通股38586股，较上期增加0.61%。 2025年1月-9月，科美诊断实现营业收入2.61亿元，同比减少24.13%；归母净利润4156.28万元，同比减 少62.94%。 分红方面，科美诊断A股上市后累计派现3.06亿元。近三年，累计派现2.38亿元。 责任 ...

Core Viewpoint - Kemei Diagnostics, established in 2007 and listed in 2021, specializes in clinical immunochemistry and has unique technological advantages in the in vitro diagnostics sector [1] Group 1: Business Performance - In Q3 2025, Kemei Diagnostics reported revenue of 261 million yuan, ranking 25th in the industry, significantly lower than the top competitor's revenue of 3.428 billion yuan [2] - The main business revenue is primarily from LiCA series products, contributing 154 million yuan, accounting for 93.42% of total revenue [2] - The net profit for the same period was 41.56 million yuan, ranking 18th in the industry, but higher than the industry median of 26.19 million yuan [2] Group 2: Financial Ratios - As of Q3 2025, Kemei Diagnostics had a debt-to-asset ratio of 20.50%, which is higher than the industry average of 18.29% [3] - The gross profit margin for the same period was 68.02%, exceeding the industry average of 56.20% [3] Group 3: Executive Compensation - The chairman and general manager, Li Lin, received a salary of 962,200 yuan in 2024, a decrease of 399,400 yuan from the previous year [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 0.60% to 10,400 [5] - The average number of circulating A-shares held per shareholder increased by 0.61% to 38,600 [5]

Financial Performance - Total revenue for Q3 2025 was ¥96,206,475.83, a decrease of 18.61% compared to the same period last year[3] - Net profit attributable to shareholders was ¥17,221,945.26, down 51.50% year-over-year[3] - The total profit for the year-to-date period decreased by 63.92% to ¥46,155,660.46[3] - Basic earnings per share for Q3 2025 was ¥0.04, a decline of 55.56% compared to the previous year[3] - The company's revenue for the reporting period was CNY 260.82 million, a year-on-year decrease of 24.13%[12] - Net profit attributable to shareholders was CNY 41.56 million, down 62.94% year-on-year[12] - Total operating revenue for the first three quarters of 2025 was CNY 260,821,861.59, a decrease of 24.1% compared to CNY 343,786,670.77 in the same period of 2024[19] - Net profit for the first three quarters of 2025 was CNY 41,562,776.02, a decline of 63.0% compared to CNY 112,150,960.47 in the same period of 2024[20] - Operating profit for the first three quarters of 2025 was CNY 45,983,456.08, down 64.0% from CNY 128,141,009.06 in the previous year[20] Research and Development - R&D investment totaled ¥20,744,668.54, representing 21.56% of total revenue, an increase of 4.92 percentage points[4] - The company continues to invest in R&D, focusing on innovative products and technologies to meet clinical needs[12] - Research and development expenses increased to CNY 56,428,488.49 in 2025, up 15.0% from CNY 48,830,331.80 in 2024[20] Cash Flow and Assets - The net cash flow from operating activities for the year-to-date period was ¥71,178,778.38, down 47.41% year-over-year[3] - Cash and cash equivalents increased to CNY 648.39 million from CNY 400.25 million as of December 31, 2024[15] - Total current assets decreased to CNY 1,030.99 million from CNY 1,067.68 million[15] - The company's cash flow from operating activities for the first three quarters of 2025 showed a significant change, reflecting ongoing adjustments in operational efficiency[22] - Cash inflow from operating activities for the first three quarters of 2025 was $300.41 million, a decrease of 27% compared to $411.58 million in the same period of 2024[23] - Net cash flow from operating activities for the first three quarters of 2025 was $71.18 million, down 47.4% from $135.33 million in 2024[24] - Total assets at the end of the reporting period were ¥1,771,711,225.11, a decrease of 3.30% from the previous year-end[4] - The company's total assets decreased to CNY 1,771,711,225.11 in 2025 from CNY 1,832,158,296.89 in 2024, a reduction of 3.3%[17] Shareholder Information - The top shareholder, Ningbo Free Trade Zone Yingweili Enterprise Management, holds 26.93% of shares[10] - The company maintained a basic and diluted earnings per share of CNY 0.10 for the first three quarters of 2025, down from CNY 0.28 in the same period of 2024[21] Operational Strategy - The company aims to enhance its product pipeline through a dual strategy of import substitution and clinical interaction[12] - The company holds a leading position with its proprietary LICA® technology platform, emphasizing cost-effective clinical products[12] - The company has a robust strategy to address unmet clinical needs and high-burden disease areas[12] Inventory and Costs - The company has maintained a stable inventory level, with inventory reported at CNY 113.82 million[15] - Total operating costs for the first three quarters of 2025 were CNY 223,690,330.27, down from CNY 234,109,060.40 in the previous year, reflecting a reduction of 4.0%[19] Liabilities and Tax - Total liabilities decreased to CNY 363,165,455.02 in 2025 from CNY 415,851,159.52 in 2024, a decline of 12.6%[17] - The company reported cash outflows for tax payments of $31.77 million in 2025, a decrease from $60.59 million in 2024, representing a reduction of 47.5%[24]

Group 1 - Company announced plans to participate in the 2025 semi-annual performance briefing for the medical device and equipment industry on September 17, 2025 [2]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2025年9月17日（星期三）下午 15:00-17:00 证券代码：688468 证券简称：科美诊断 公告编号：2025-020 会议召开地点：上海证券交易所上证路演中心 公司于2025年8月30日在上海证券交易所网站（www.sse.com.cn）发布了《 2025年半年度报告》，为便于广大投资者更全面深入地了解公司2025年半年度的 经营成果、财务状况，公司计划于2025年9月17日下午15:00-17:00参加由上海证 券交易所主办的2025年半年度科创板医疗器械及医疗设备行业集体业绩说明会， 就投资者关心的问题进行交流。 一、说明会类型 （网址：https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络文字互动 投资者可于2025年9月16日（星期二）16:00前通过科美诊断技术股份有限 公司（以下简称"公司"）邮箱ir@chemclin.com进行提问。公司将在说明会上 对投资者普遍关注的问题进行回答 ...

Group 1 - The core point of the article is the appointment of Mr. Huang Zhengming as the Vice General Manager of Kemei Diagnostics [2][3]

Group 1 - The core point of the article is the appointment of Mr. Li Lin as the new General Manager of Kemei Diagnostics [2][3]

Group 1 - The company announced the appointment of Ms. Huang Yanling as the Chief Financial Officer and Secretary of the Board [1]

Core Viewpoint - Company announced the appointment of Mr. Li Shiyang as the representative for securities affairs [1] Group 1 - Company made a public announcement regarding the hiring of a new securities affairs representative [1]